Papel del dominio V1/V2 de la glucoproteína 120 del virus de la inmunodeficiencia humana de tipo 1 en la inducción de anticuerpos neutralizantes

Letvin, 2003, Immunopathogenesis and immunotherapy in AIDS virus infections, Nat Med, 9, 861, 10.1038/nm0703-861 Wyatt, 1998, The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens, Science, 280, 1884, 10.1126/science.280.5371.1884 Pilgrim, 1997, Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection, J Infect Dis, 176, 924, 10.1086/516508 Stiehm, 1995, Summary of the workshop on passive immunotherapy in the prevention and treatment of HIV infection. The Passive Antibody Workshop Participants, Clin Immunol Immunopathol, 75, 84, 10.1006/clin.1995.1056 Binley, 2004, Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies, J Virol, 78, 13232, 10.1128/JVI.78.23.13232-13252.2004 Burton, 1994, Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody, Science, 266, 1024, 10.1126/science.7973652 Li, 2006, Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants, J Virol, 80, 1414, 10.1128/JVI.80.3.1414-1426.2006 Wu, 2006, Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope, Vaccine, 24, 4995, 10.1016/j.vaccine.2006.03.083 Pinter, 2004, The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection, J Virol, 78, 5205, 10.1128/JVI.78.10.5205-5215.2004 McKnight, 1995, Immune escape and tropism of HIV, Trends Microbiol, 3, 356, 10.1016/S0966-842X(00)88975-1 Earl, 1993, Mutational analysis of the assembly domain of the HIV-1 envelope glycoprotein, AIDS Res Hum Retroviruses, 9, 589, 10.1089/aid.1993.9.589 Gaschen, 2002, Diversity considerations in HIV-1 vaccine selection, Science, 296, 2354, 10.1126/science.1070441 Profy, 1990, Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual, J Immunol, 144, 4641, 10.4049/jimmunol.144.12.4641 Starcich, 1986, Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS, Cell, 45, 637, 10.1016/0092-8674(86)90778-6 Modrow, 1987, Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: Prediction of antigenic epitopes in conserved and variable regions, J Virol, 61, 570, 10.1128/JVI.61.2.570-578.1987 Mondor, 1998, Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans, J Virol, 72, 3623, 10.1128/JVI.72.5.3623-3634.1998 Fortin, 1998, T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1, J Virol, 72, 2105, 10.1128/JVI.72.3.2105-2112.1998 Nisole, 1999, The anti-HIV pseudopeptide HB-19 forms a complex with the cell-surface-expressed nucleolin independent of heparan sulfate proteoglycans, J Biol Chem, 274, 27875, 10.1074/jbc.274.39.27875 Wu, 2002, Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission, J Virol, 76, 5905, 10.1128/JVI.76.12.5905-5914.2002 Moore, 1992, Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates, J Virol, 66, 235, 10.1128/JVI.66.1.235-243.1992 Nisole, 2004, Early steps of retrovirus replicative cycle, Retrovirology, 1, 9, 10.1186/1742-4690-1-9 Dalgleish, 1984, The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus, Nature, 312, 763, 10.1038/312763a0 Deng, 1996, Identification of a major co-receptor for primary isolates of HIV-1, Nature, 381, 661, 10.1038/381661a0 Choe, 1996, The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates, Cell, 85, 1135, 10.1016/S0092-8674(00)81313-6 Moore, 1997, Coreceptors: Implications for HIV pathogenesis and therapy, Science, 276, 51, 10.1126/science.276.5309.51 Moore, 2003, The entry of entry inhibitors: A fusion of science and medicine, Proc Natl Acad Sci USA, 100, 10598, 10.1073/pnas.1932511100 Gallo, 2003, The HIV Env-mediated fusion reaction, Biochim Biophys Acta, 1614, 36, 10.1016/S0005-2736(03)00161-5 Zolla-Pazner, 2004, Identifying epitopes of HIV-1 that induce protective antibodies, Nat Rev Immunol, 4, 199, 10.1038/nri1307 Markel, 2005, The search for effective HIV vaccines, N Engl J Med, 353, 753, 10.1056/NEJMp058146 Moog, 1997, Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals, J Virol, 71, 3734, 10.1128/JVI.71.5.3734-3741.1997 Aasa-Chapman, 2004, Development of the antibody response in acute HIV-1 infection, Aids, 18, 371, 10.1097/00002030-200402200-00002 Frost, 2005, Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection, Proc Natl Acad Sci USA, 102, 18514, 10.1073/pnas.0504658102 Hansen, 1990, Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: Peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization, J Virol, 64, 2833, 10.1128/JVI.64.6.2833-2840.1990 Scanlan, 2002, The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1--> 2 mannose residues on the outer face of gp120, J Virol, 76, 7306, 10.1128/JVI.76.14.7306-7321.2002 Hioe, 1998, Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization, AIDS Res Hum Retroviruses, 14, S247 Ho, 1991, Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody, J Virol, 65, 489, 10.1128/JVI.65.1.489-493.1991 Karwowska, 1992, Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120, AIDS Res Hum Retroviruses, 8, 1099, 10.1089/aid.1992.8.1099 Thali, 1993, Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding, J Virol, 67, 3978, 10.1128/JVI.67.7.3978-3988.1993 Labrijn, 2003, Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1, J Virol, 77, 10557, 10.1128/JVI.77.19.10557-10565.2003 Xiang, 2002, Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies, AIDS Res Hum Retroviruses, 18, 1207, 10.1089/08892220260387959 Gorny, 1994, Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1, J Virol, 68, 8312, 10.1128/JVI.68.12.8312-8320.1994 Gorny, 2002, Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades, J Virol, 76, 9035, 10.1128/JVI.76.18.9035-9045.2002 Gorny, 1992, Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody, J Virol, 66, 7538, 10.1128/JVI.66.12.7538-7542.1992 Scott, 1990, Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain, Proc Natl Acad Sci USA, 87, 8597, 10.1073/pnas.87.21.8597 Trkola, 1995, Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG, J Virol, 69, 6609, 10.1128/JVI.69.11.6609-6617.1995 Zwick, 2001, Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41, J Virol, 75, 10892, 10.1128/JVI.75.22.10892-10905.2001 Pantophlet, 2006, GP120: Target for neutralizing HIV-1 antibodies, Annu Rev Immunol, 24, 739, 10.1146/annurev.immunol.24.021605.090557 Hessell, 2007, Fc receptor but not complement binding is important in antibody protection against HIV, Nature, 449, 101, 10.1038/nature06106 Dowbenko, 1988, Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies, J Virol, 62, 4703, 10.1128/JVI.62.12.4703-4711.1988 Goudsmit, 1988, Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts, Aids, 2, S41, 10.1097/00002030-198800001-00006 Broliden, 1992, Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins, Proc Natl Acad Sci USA, 89, 461, 10.1073/pnas.89.2.461 Scala, 1999, Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera, J Immunol, 162, 6155, 10.4049/jimmunol.162.10.6155 Parker, 2001, Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5, J Virol, 75, 10906, 10.1128/JVI.75.22.10906-10911.2001 Coeffier, 2000, Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein, Vaccine, 19, 684, 10.1016/S0264-410X(00)00267-X Barbas, 1992, Recombinant human fab fragments neutralize human type 1 immunodeficiency virus in vitro, Proc Natl Acad Sci USA, 89, 9339, 10.1073/pnas.89.19.9339 Leonard, 1990, Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells, J Biol Chem, 265, 10373, 10.1016/S0021-9258(18)86956-3 Trkola, 1996, Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1, J Virol, 70, 1100, 10.1128/JVI.70.2.1100-1108.1996 Calarese, 2003, Antibody domain exchange is an immunological solution to carbohydrate cluster recognition, Science, 300, 2065, 10.1126/science.1083182 McMichael, 2003, HIV vaccines 1983-2003, Nat Med, 9, 874, 10.1038/nm0703-874 Fung, 1992, Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120, J Virol, 66, 848, 10.1128/JVI.66.2.848-856.1992 Javaherian, 1989, Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein, Proc Natl Acad Sci USA, 86, 6768, 10.1073/pnas.86.17.6768 Goudsmit, 1988, Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees, Proc Natl Acad Sci USA, 85, 4478, 10.1073/pnas.85.12.4478 Mascola, 1996, J Infect Dis, 173, 340, 10.1093/infdis/173.2.340 Conley, 1994, Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D, J Virol, 68, 6994, 10.1128/JVI.68.11.6994-7000.1994 Gorny, 2004, The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope, J Virol, 78, 2394, 10.1128/JVI.78.5.2394-2404.2004 Cormier, 2002, The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor, J Virol, 76, 8953, 10.1128/JVI.76.17.8953-8957.2002 Kwong, 2000, Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus, J Virol, 74, 1961, 10.1128/JVI.74.4.1961-1972.2000 Wyatt, 1993, Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions, J Virol, 67, 4557, 10.1128/JVI.67.8.4557-4565.1993 Huang, 2005, Structure of a V3-containing HIV-1 gp120 core, Science, 310, 1025, 10.1126/science.1118398 Chakraborty, 2006, Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies, Biochem J, 399, 483, 10.1042/BJ20060588 Koito, 1994, Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization, J Virol, 68, 2253, 10.1128/JVI.68.4.2253-2259.1994 Westervelt, 1992, Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo, J Virol, 66, 2577, 10.1128/JVI.66.4.2577-2582.1992 Sullivan, 1993, Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody, J Virol, 67, 3674, 10.1128/JVI.67.6.3674-3679.1993 Toohey, 1995, Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread, Virology, 213, 70, 10.1006/viro.1995.1547 Stamatatos, 1998, Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication, AIDS Res Hum Retroviruses, 14, 1129, 10.1089/aid.1998.14.1129 Wyatt, 1995, Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding, J Virol, 69, 5723, 10.1128/JVI.69.9.5723-5733.1995 Sullivan, 1998, CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization, J Virol, 72, 4694, 10.1128/JVI.72.6.4694-4703.1998 Vijh-Warrier, 1995, Characterization of the variable regions of a chimpanzee monoclonal antibody with potent neutralizing activity against HIV-1, Mol Immunol, 32, 1081, 10.1016/0161-5890(95)00081-X Warrier, 1994, A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody, J Virol, 68, 4636, 10.1128/JVI.68.7.4636-4642.1994 Vijh-Warrier, 1996, Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site, J Virol, 70, 4466, 10.1128/JVI.70.7.4466-4473.1996 Wu, 1995, Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: Role of glycosylation in the correct folding of the V1/V2 domain, J Virol, 69, 2271, 10.1128/JVI.69.4.2271-2278.1995 Pinter, 2005, The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates, J Virol, 79, 6909, 10.1128/JVI.79.11.6909-6917.2005 Rong, 2007, Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection, J Virol, 81, 1350, 10.1128/JVI.01839-06 Krachmarov, 2006, Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1, J Virol, 80, 7127, 10.1128/JVI.02619-05 Rizzuto, 1998, A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding, Science, 280, 1949, 10.1126/science.280.5371.1949 Wei, 2003, Antibody neutralization and escape by HIV-1, Nature, 422, 307, 10.1038/nature01470 Gorny, 2005, Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles, J Virol, 79, 5232, 10.1128/JVI.79.8.5232-5237.2005 Ho, 1991, Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody, Proc Natl Acad Sci USA, 88, 8949, 10.1073/pnas.88.20.8949 Cao, 1997, Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein, J Virol, 71, 9808, 10.1128/JVI.71.12.9808-9812.1997 Wolk, 2006, N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization, Med Microbiol Immunol, 195, 165, 10.1007/s00430-006-0016-z Kwong, 2002, HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites, Nature, 420, 678, 10.1038/nature01188 Kim, 2003, Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies, Virology, 305, 124, 10.1006/viro.2002.1727 Krachmarov, 2005, Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking, J Virol, 79, 780, 10.1128/JVI.79.2.780-790.2005